The Health Technology Assessment (HTA) Accelerator from IQVIA lets you analyze past and current payer assessments and evidence requirements to guide clinical trial design and market access strategy across the product lifecycle. Analyze the numbers of Single drug assessments in Lung cancer from January 2011 till July 2022. If you need more detailed analysis, request your trial access: https://www.iqvia.com/form-pages/demo
IQVIA is using vast quantities of data in powerful new ways. See how we can help you tap into information from past trials, patient reported outcomes and other sources to accelerate your research.
Access clearer, more compelling support to demonstrate the value of your product.
Get insights into payer decision making and evidence requirements to accelerate market access for your drug.
